Am­gen com­mits to low-cost Repatha; AZTher­a­pies bags Smith Ther­a­peu­tic­s' CAR-Treg tech for neu­roin­flam­ma­tion

→ As Am­gen tracks mod­est growth of its Repatha fran­chise and braces for the ar­rival of cheap­er cho­les­terol-low­er­ing med­i­cines in the mar­ket, its com­mer­cial team is go­ing one step fur­ther to try and boost adop­tion of its PC­SK9 drug.

Repatha’s list price will now be $5,850 across the board, not co-ex­ist­ing with the high­er cost op­tion. First in­tro­duced in Oc­to­ber 2018, that num­ber rep­re­sent­ed a 60% dis­count to the orig­i­nal $14,100 per year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER